Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)
These protocols are based on clinical observation, not randomized controlled trials
doi: 10.1016/j.cmet.2013.03.002 149 KlugeMAFettermanJLVitaJA
A1C / Prediabetes Control+ GLP-1/GIP Contains Tirzepatide and Inositol Compounded oral microdose of Tirzepatide and Inositol, formulated to help support balanced glucose metabolism and healthy insulin response
Strict safety protocols, including mandatory lab work before prescribing any medication
US$ 24.24
US$ 23.47
US$ 20.74
US$ 29.47
US$ 25.73
US$ 28.12
US$ 29.52
US$ 21.15
US$ 29.03
US$ 24.20
